CIONIC, the "bionic" clothing company behind the Cionic Neural Sleeve, today announced a $12.5 million Series A financing. This funding follows the Cionic Neural Sleeve’s FDA clearance earlier this year and fuels the manufacturing and delivery of its mobility technology to the millions of people living with multiple sclerosis, stroke, cerebral palsy, and other mobility impairments.
The Cionic Neural Sleeve analyzes, predicts and augments a person’s movement. It uses an array of sensors to measure how the body is positioned and how individual muscles fire during movement, predicts intended movement by measuring the electrical signal from the brain, and then algorithms analyze this data in real time to determine optimal muscle activation patterns. The Neural Sleeve then delivers Functional Electrical Stimulation to sequence proper muscle firing for natural movement. It is an adaptive system that provides real-time augmentation and adjustment of the wearer’s movement, updating each time they take a step.
“We are on the precipice of a global mobility crisis, as twenty percent of the world’s population is projected to have a movement disability by 2050. It’s time to bring technological innovation to this growing problem. Forward-looking investors realize that we need to take action today, and we are proud to be backed by a group of investors who recognize the need for better solutions and have joined us in our mission to redefine human mobility,” said Jeremiah Robison, Founder and CEO of CIONIC.
To date, the company has raised $23 million to build a platform for human augmentation. The Cionic Neural Sleeve is the first product to ship on this platform. The Series A financing will accelerate research trials and commercialization of additional indications, driving a robust product pipeline across the spectrum of human mobility. CIONIC is scaling up its team in key functions such as R&D, engineering, operations, marketing, and customer service to support the next stage of growth.